SHP-201 / Shape Therapeutics - LARVOL DELTA

Shape Therapeutics Shares Breakthrough Preclinical Data for Non-Invasive Treatment of Parkinson’s Disease Using a Brain Targeted AAV Gene Therapy at the European Society of Gene & Cell Therapy 32nd Annual Congress (GlobeNewswire) - "AAV5 exhibits substantially lower seroprevalence, offering a more favorable immune profile. SHP-DB1 was created through a multi-stage screen of over 1 billion AAV capsids in non-human primates (NHPs), followed by iterative optimization. The capsid incorporates additional engineering that enhances post-entry trafficking and boosts payload expression in transduced cells, overcoming an intrinsic limitation of AAV5...Most strikingly, SHP-DB1 achieves 96% neuronal transduction in the substantia nigra, a critical region for Parkinson’s Disease therapy...SHP-201 appears to be very well tolerated in vivo across species..."

Preclinical • Parkinson's Disease